APA (7th ed.) Citation

Ventura, I., Salcedo, N. P., Pérez-Bermejo, M., Pérez-Murillo, J., Tejeda-Adell, M., Tomás-Aguirre, F., . . . Murillo-Llorente, M. T. (2025). Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review. International Journal of Molecular Sciences, 26(5), 1908. https://doi.org/10.3390/ijms26051908

Chicago Style (17th ed.) Citation

Ventura, Ignacio, Nerea Pinilla Salcedo, Marcelino Pérez-Bermejo, Javier Pérez-Murillo, Manuel Tejeda-Adell, Francisco Tomás-Aguirre, María Ester Legidos-García, and María Teresa Murillo-Llorente. "Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review." International Journal of Molecular Sciences 26, no. 5 (2025): 1908. https://doi.org/10.3390/ijms26051908.

MLA (9th ed.) Citation

Ventura, Ignacio, et al. "Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review." International Journal of Molecular Sciences, vol. 26, no. 5, 2025, p. 1908, https://doi.org/10.3390/ijms26051908.